Abbott(NYSE: ABT)+ today announced a major product launch, broadening the population that can utilize its continuous glucose monitoring (CGM) technology.

Our sister site, Drug Delivery Business News, reports that Abbott made its Lingo CGM system available without a prescription in the U.S.

Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre CGM technology platform.

Abbott received FDA clearance for Lingo and its Libre Rio over-the-counter (OTC) CGMs in June. The launch highlights the industry’s move beyond prescription CGMs, as Dexcom also launched its own Stelo OTC CGM last week.